SG Americas Securities, LLC
Broker-DealerPosition in ESTA — Establishment Labs Holdings Inc.
CIK 1313360
NEW YORK, NY
Position in ESTA
as of Mar 31, 2026
· filed Apr 16, 2026
Position Value
$2,153,551
+$973,916 QoQ
Shares Held
37,928
+134.3% QoQ
Ownership
0.129%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2021
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ESTA Over Time
Shares Held
Position Value (USD)
Position in Medical Devices
Healthcare · as of Mar 31, 2026SG Americas Securities, LLC holds $1,448,173,425 across 49 Medical Devices names. ESTA ranks #21 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | SYK |
Stryker Corp
|
1,525,239 | $501,178,283 | |
| 2 | ABT |
Abbott Laboratories
|
2,064,157 | $211,926,999 | |
| 3 | DXCM |
Dexcom Inc
|
2,065,277 | $129,699,395 | |
| 4 | MASI |
Masimo Corp
|
522,824 | $92,994,704 | |
| 5 | EW |
Edwards Lifesciences Corp
|
980,609 | $78,527,168 | |
| 6 | PODD |
Insulet Corp
|
318,848 | $66,907,064 | |
| 7 | BSX |
Boston Scientific Corp
|
931,155 | $58,429,976 | |
| 8 | NEOG |
Neogen Corp
|
6,266,033 | $58,211,446 |
All Filings in ESTA
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,153,551 | 37,928 | Shares | Sole | 2026-04-16 | |
| 2025-12-31 | $1,179,635 | 16,186 | Shares | Sole | 2026-01-09 | |
| 2025-09-30 | $414,408 | 10,110 | Shares | Sole | 2025-10-23 | |
| 2025-06-30 | $372,089 | 8,712 | Shares | Sole | 2025-08-08 | |
| 2025-03-31 | $183,073 | 4,486 | Shares | Sole | 2025-04-15 | |
| 2024-06-30 | $302,539 | 6,658 | Shares | Sole | 2024-07-12 | |
| 2023-12-31 | $120,026 | 4,636 | Shares | Sole | 2024-01-12 | |
| 2022-03-31 | $202,372 | 3,003 | Shares | Sole | 2022-04-29 | |
| 2021-06-30 | $840,996 | 9,629 | Shares | Sole | 2021-08-12 | |
| No filing history on record for this holder in this stock. | ||||||